<DOC>
	<DOCNO>NCT01964170</DOCNO>
	<brief_summary>To compare efficacy safety ASP3550 goserelin acetate patient prostate cancer .</brief_summary>
	<brief_title>A Study Compare Effect ASP3550 With Goserelin Patients With Prostate Cancer</brief_title>
	<detailed_description>This study consist two part . The purpose PART 1 test non-inferiority ASP3550 goserelin acetate respect cumulative castration rate term serum testosterone ASP3550 goserelin acetate administer one-year patient prostate cancer . The patient assign receive ASP3550 complete treatment PART 1 eligible treatment PART 2 , receive ASP3550 maintenance dose subcutaneously additional term . The long-term safety , efficacy PK continue ASP3550 treatment assess PART 2 .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<criteria>Male patient histologically confirm prostate cancer ( adenocarcinoma ) . Patient endocrine treatment indicate . Patient undergo prostatectomy radiotherapy curative intention rise serum PSA ( PSA ≥ 2 ng/mL screen ) may include . Has serum testosterone level 2.2 ng/mL screening . Has Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) score 0 2 screening . Has serum PSA ≥ 2 ng/mL screening . Has life expectancy least 12 month . Previous present endocrine treatment prostate cancer . Example : surgical castration , GnRH agonists , GnRH antagonists , antiandrogens oestrogen , 5αreductase inhibitor . Received 5αreductase inhibitor within 25 week precede screening . Is candidate curative therapy , i.e. , radical prostatectomy radiotherapy within 12 month . Has concurrent history poorly control severe asthma , anaphylactic reaction , severe urticaria angioedema . Has hypersensitivity towards mannitol . Has mark prolongation QT/QTc interval ( two consecutive increase &gt; 450 m QTc interval retest ) screening . Has concurrent history disease ( heart failure , hypokalemia , family history QT prolongation syndrome , etc . ) may induce Torsade de Pointes .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>ASP3550</keyword>
	<keyword>Prostate cancer</keyword>
</DOC>